Lv1
45 积分 2021-09-28 加入
Beyond viral suppression: assessing the immunotherapeutic potential of bepirovirsen for chronic hepatitis B
13小时前
待确认
Beyond ALT flares: rethinking immune activation and mechanistic interpretation in bepirovirsen-treated chronic hepatitis B
13小时前
已完结
Comment on ‘Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)’
13小时前
已完结
Beyond immune activation: unresolved questions in bepirovirsen’s mechanism of action toward HBV functional cure
13小时前
已完结
PBPK Modelling of Antisense Oligonucleotide Therapeutics: Application for Predicting Plasma and Tissue Pharmacokinetics of Bepirovirsen
13小时前
已完结
Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study
14小时前
已完结
Bepirovirsen/GSK3389404: Antisense or TLR9 agonists?
15小时前
已完结
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
18小时前
已完结
Creating Glepaglutide: The First Long-Acting GLP-2 Analogue to enable a Ready-to-Use Subcutaneous Injection
4个月前
已完结
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
4个月前
已完结
皖公网安备34019202002308
